首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   3721篇
  免费   193篇
  国内免费   44篇
儿科学   1篇
妇产科学   1423篇
基础医学   243篇
临床医学   281篇
内科学   60篇
皮肤病学   51篇
神经病学   7篇
特种医学   62篇
外科学   252篇
综合类   631篇
预防医学   397篇
药学   302篇
  2篇
中国医学   211篇
肿瘤学   35篇
  2024年   3篇
  2023年   26篇
  2022年   101篇
  2021年   110篇
  2020年   83篇
  2019年   104篇
  2018年   93篇
  2017年   101篇
  2016年   118篇
  2015年   130篇
  2014年   292篇
  2013年   318篇
  2012年   255篇
  2011年   328篇
  2010年   294篇
  2009年   252篇
  2008年   191篇
  2007年   187篇
  2006年   217篇
  2005年   166篇
  2004年   135篇
  2003年   81篇
  2002年   94篇
  2001年   67篇
  2000年   36篇
  1999年   28篇
  1998年   21篇
  1997年   25篇
  1996年   14篇
  1995年   24篇
  1994年   27篇
  1993年   13篇
  1992年   3篇
  1991年   1篇
  1990年   4篇
  1989年   2篇
  1988年   2篇
  1986年   2篇
  1985年   1篇
  1984年   3篇
  1983年   1篇
  1982年   1篇
  1981年   2篇
  1980年   1篇
  1975年   1篇
排序方式: 共有3958条查询结果,搜索用时 734 毫秒
1.
Catamenial hemothorax is a rare manifestation of thoracic endometriosis syndrome. It is commonly seen associated with pelvic endometriosis in nulliparous reproductive-age women. Most cases are minor and self-limiting. We present a case of a 32-year-old woman who presented with prolonged worsening dyspnea and was found to have a massive hemothorax on evaluation.  相似文献   
2.
3.
目的:探讨沙利度胺(thalidomide)对子宫内膜异位症(endometriosis,EMs)病灶生长和血管生成的影响,为从抗血管途径治疗EMs提供依据.方法:将EMs患者在位子宫内膜种植于重度复合性免疫缺陷病(severe combined immunodeficiency disease, SCID)小鼠皮下,建立EMs鼠模型.接种后第3周给予治疗,治疗组(n=10)腹腔注射沙利度胺50mg/kg/d,对照组(n=10)腹腔注射等体积PBS,连用14d;每隔3d测量异位病灶体积一次;病灶组织采用免疫组化法测定病灶微血管密度(microvessel density,MVD)及血管内皮生长因子(VEGF)的表达.结果:SCID小鼠皮下种植内异症模型内膜存活率高且观察方便;治疗组病灶体积增长有缩小趋势,但与对照组相比差异无统计学意义(P>0.05);治疗组MVD显著低于对照组(P<0.05);治疗组和对照组VEGF的表达差异无统计学意义(P>0.05).结论:沙利度胺对EMs异位病灶的血管生成有明显抑制作用;抑制VEGF的表达可能不是沙利度胺抑制EMs血管生成的主要原因.  相似文献   
4.
目的:检测子宫内膜异位症(内异症)患者血清中差异表达的蛋白。方法:采用表面增强激光解吸/离子化飞行时间质谱(SELDI—TOF—MS)技术,选用WCX2蛋白质芯片对50例内异症及48例对照组血清标本进行检测以筛选内异症血清中差异表达的蛋白。结果:在Mr 0~50000范围内,检测出106个蛋白峰。内异症患者血清中差异表达的蛋白峰有4个。将发现的差异蛋白峰在Swiss蛋白数据库中搜索,发现Mr 9280蛋白峰与玻璃粘连蛋白Vitronectin相符。Vitronectin属于整合素家族,在内异症的粘附、侵袭、血管形成过程中起重要作用。其他的蛋白峰没有发现与之相匹配的蛋白,提示可能为新的蛋白质。结论:内异症患者血清中存在差异表达的蛋白,其对内异症的早期诊断具有一定的临床意义。SELDI蛋白芯片技术是一种快速、简单易行、样本用量少、高通量、重复性好的分析方法,具有广阔的临床应用前景。  相似文献   
5.
目的观察褪黑素(MT)对大鼠子宫内膜异位症(EM)模型细胞凋亡调控相关蛋白的影响。方法采用手术移植法制备大鼠EM模型,大鼠随机分为正常对照组、模型对照组和MT高、低剂量组,免疫组织化学法检测异位内膜Bcl-2、Fas、细胞间粘附分子(ICAM)-1的表达,同时检测脾脏自然杀伤(NK)细胞活性。结果MT治疗组与模型组比较异位内膜Bcl-2、ICAM-1表达明显下降,Fas表达明显升高,脾脏NK细胞活性显著增加。结论MT具有抑制异位内膜Bcl-2、ICAM-1表达以及增强Fas表达和脾脏NK细胞活性的作用。  相似文献   
6.
作者将29例子宫内膜异位症(简称异位症)患者的异位和在位内膜进行离体组织孵育,应用放射免疫方法检测孵育液中泌乳素(PRL)含量;同时应用ABC免疫酶标记法确定异位和在位内膜分泌PRL的部位,结果异位和在位内膜离体组织经0~24h孵育,孵育液中PRL含量均显著增加(P<0.05);继续孵育至48h,PRL含量不再增加。但异位内膜分泌PRL的活性低于自身在位内膜。免疫组化PRL检测,异位和在位内膜分别有4和6例呈PRL阳性反应。组织学对照现察,内膜成熟上皮细胞数及前蜕膜细胞数越多者,其相应孵育液中PRL含量越高,免疫组化PRL阳性反应也越强。提示异位内膜PRL分泌特点与其自身在位内膜不完全相同,可能与病理环境有关。  相似文献   
7.
目的:重视尿路子宫内膜异位症,探讨其诊断,治疗方法,方法:对3例尿路子宫内膜异位症的临床表现和B超,CT,膀胱镜征象以及治疗方法进行分析。结果:术前明确诊断2例,术中发现1例,术后均病理证实,无复发,痊愈出院,疗效满意。结论:确诊需靠腔镜检查或手术探查,诊断应强调详细地询问病史,治疗方法的选择决定于子宫内膜异位症的部位。  相似文献   
8.
OBJECTIVE: This study was designed to determine the relationship between interstitial cystitis (IC), endometriosis (endo), and chronic pelvic pain (CPP) in individuals in whom nongynecological and nonurological problems had been previously ruled out. METHODS: A prospective study of 162 consecutive women with a complaint of chronic pelvic pain seen in the clinic was performed between August 2002 and December 2005. These patients underwent a workup to exclude other causes of pelvic pain, had PUF (Pain Urgency and Frequency) questionnaires filled out, and underwent a laparoscopy and a cystoscopy with hydrodistention. Pain levels were determined, and treatment was reviewed and enumerated. Results were obtained and quantified. RESULTS: In this study, 123 (76%) patients were diagnosed with active endometriosis, 133 (82%) were diagnosed with interstitial cystitis, and 107 (66%) had both disease entities simultaneously. Thirteen (8%) patients were diagnosed with pathologies unrelated to endometriosis and interstitial cystitis. Pain levels were seen to decrease at 6 months in all groups of patients with the exception of those patients with endometriosis only. CONCLUSION: CPP is a difficult, taxing, and frustrating concern for many women in the United States. These individuals have traditionally been difficult to treat. A large number of women with CPP in our patient population have been shown to have endometriosis, interstitial cystitis, or both. Therefore, a workup for premenopausal individuals with CPP involves obtaining a history that keys into possible nongynecologic causes of pain, a complete accounting of urinary problems, and a thorough history of gynecological problems. A physical examination with a comprehensive history should be performed, and the investigation may include the possibility of a simultaneous laparoscopy and cystoscopy if warranted. These procedures can serve as both a means for diagnosis and treatment of these problems when encountered.  相似文献   
9.
目的研究17β-雌二醇(17β-E2)对子宫内膜异位症(内异症)患者在位子宫内膜间质细胞β-catenin mRNA和蛋白表达的影响,探讨Wnt/β-catenin信号通路在介导雌激素促进内异症发生发展的作用。方法体外分离培养内异症患者在位子宫内膜间质细胞。用不同浓度17β-E2处理子宫内膜间质细胞48 h;此后选用10-10mol/L 17β-E2处理子宫内膜间质细胞12、24和48 h,逆转录聚合酶链反应(RT-PCR)和免疫印迹法(Western blotting)检测17β-E2处理前后子宫内膜间质细胞β-catenin mRNA和蛋白的表达水平。同法分析雌激素受体拮抗剂ICI182,780(10-6mol/L)对17β-E2促进β-catenin mRNA和蛋白表达的影响。免疫组织化学染色观察17β-E2作用后β-catenin在子宫内膜间质细胞中的定位。结果17β-E2能明显促进内异症患者在位子宫内膜间质细胞β-catenin mRNA和蛋白的表达,并呈剂量和时间依赖性,于10-10mol/L作用48 h最明显。雌激素受体拮抗剂ICI182,780能明显抑制17β-E2对子宫内膜间质细胞β-catenin mRNA和蛋白的表达。免疫组织化学染色发现17β-E2能促进β-catenin在子宫内膜间质细胞核内的表达。结论雌激素可能通过激活Wnt/β-catenin信号通路促进内异症在位子宫内膜的异位种植。  相似文献   
10.
OBJECTIVES: To evaluate the sensitivity to change of the Endometriosis Health Profile-30 (EHP-30) questionnaire. SETTING: The Women's Center, John Radcliffe Hospital, Oxford. DESIGN: Postal survey to 66 women undergoing conservative surgery for the treatment of endometriosis-associated pain. The EHP-30 and the Short Form-36 (SF-36) were administered 2 weeks before the operation, and 4 months post-operatively. At T2 a transition question was included to evaluate changes in patients health status. To evaluate responsiveness effect sizes, standardised response means, the index of responsiveness and the minimally and clinically important differences were calculated. RESULTS: Forty (66.6%) patients returned the questionnaires at time 1 and 2. Overall less responsive effect size scores were found for the SF-36 (0.1-0.5) compared to the EHP-30 (-0.1-1.1) for all patients who had undergone treatment. Minimally important differences and the index of responsiveness were overall higher for the EHP-30 (0.4-2.0) compared to the SF-36 (0.1-1.0). Change scores for four of the five scales were significantly correlated with women's responses to the transition question. CONCLUSIONS: Results suggest that the EHP-30 is sensitive to change. Its application in clinical trials should prove beneficial in assessing the impact of medical and surgical interventions upon quality of life for women with endometriosis.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号